Last reviewed · How we verify
Diabetes — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tryvio | APROCITENTAN | Idorsia | Endothelin Receptor Antagonist [EPC] | 2025-01-01 | ||
| olmesartan medoxomil-hydrochlorothiazide | OLMESARTAN | Cosette | Thiazide Diuretic [EPC] | 2019-01-01 | ||
| Lisinopril/HCTZ | HCTZ | Direct_Rx | Thiazide Diuretic [EPC] |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Cosette · 1 drug in Diabetes
- Direct_Rx · 1 drug in Diabetes
- Idorsia · 1 drug in Diabetes
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diabetes:
- Diabetes treatment updates — RSS
- Diabetes treatment updates — Atom
- Diabetes treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diabetes — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes. Accessed 2026-06-10.
Related
- Diabetes full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing